• State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral and Maxillofacial Surgery & Dept. of Evidence-Based Dentistry, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P.R.China;
HUA Chengge, Email: huacg@163.com
Export PDF Favorites Scan Get Citation

RoB2 (revised version 2019), an authoritative tool for assessing the risk of bias in randomized controlled trials, has been updated and improved based on the original version. This article elaborated and interpreted the background and main content of RoB2 (revised version 2019), as well as the operation process of the new software. Compared with the previous version of RoB2 (revised version 2018), RoB2 (revised version 2019) has the advantages of rich content, complete details, accurate questions, and simple operation, etc. Additionally, it is more user-friendly for researchers and beginners. The risk bias assessment of randomized controlled trials is more comprehensive and accurate, and it is an authoritative, trustworthy, and popular tool for evaluating the risk of bias in randomized controlled studies in medical practice.

Citation: LIU Jinchi, LIU Chang, HUA Chengge. Risk bias assessment tool RoB2 (revised version 2019) for randomized controlled trial : an interpretation. Chinese Journal of Evidence-Based Medicine, 2021, 21(6): 737-744. doi: 10.7507/1672-2531.202011144 Copy

  • Previous Article

    Statistical methods in pragmatic randomized controlled trials (Ⅱ): Addressing missing outcome data